MY GUESS IS THEY GIVE US AN UPDATE ON RG-102 AND........ HOPFULLY WITH THE 33MILLION THEY GET FROM NOVARTIS, THEY DO A STOCK BUYBACK....EXCUSE ME!!
my thinking is this, if the results due out soon are good, the deal with aztra zen to pay rgls 33 million$$ and take over cost for the drug will be out the window....it makes sense they buy the whole company for 5 bucks a share and if they are bad then we pin our hopes on otherdrugs in the pipe but as you can see from insiders purchases at .91 cents.... this is a very good lottery ticket that should pay off to at least 3x the price of today....imagine they actually get some good results? does anyone know exactly when the results will be posted on FDAtrials.gov ???
Looking forward to this week's conference and the fallout. Something good has to happen, you would think.
The stock is showing some staying power. Delisting not imminent. The clock starts again when share price closes at or above $1.
SLNO (MC $18 M) BLOCKBUSTER in Phase 3 /Rare Disease & Orphan Status = REAL Unknown low float stock with 1000% upside Potential and more .Next billion dollar rare disease company like SRPT here .GLTA
Soleno therapeutics (SLNO)
Market Cap $18 Million Cash: $8 Million Price $0.37
Shares Out: 47.6 Million ( 36 Million shares held by Insiders & Institutions)
•Company expects to initiate pivotal Phase III clinical trial by year-end 2017; will take approximately 9-12 months to complete
Soleno Therapeutics, Inc. (Soleno) is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company is currently advancing its lead candidate, DCCR, a once-daily oral tablet for the treatment of PWS, into a Phase III clinical development program at the end of 2017.
Market Opportunity for PWS is Substantial.
While the lack of approved treatments for PWS alone make it difficult to assess the market, sales of Pfizer’s (NYSE: PFE) Genotrop in (somatropin) can provide some insight despite being indicate for PWS, in addition to, growth failure due to growth hormone deficiency(GHD),Turner syndrome,idiopathic short stature,and small for gestational age.This product achieved its highest revenue in 2008,with worldwide sales of approximately $900 million.While somatropin has been proven to improve growth and body composition, it does not affect the key disease component of hyperphagia and use is associated with substantial risk. Soleno is developing DCCR for the treatment of PWS,to help address the unmet need of this patient population. To assess the potential of DCCR for PWS, we performed a scenario analysis, which indicates that annual sales could be in the range of $1.1 billion given a moderate price point and 50% market penetrance.
Regulus: A 'Lottery Ticket' Only For The Brave-Hearted
Today we look at a small cap biotech concern and 'Busted IPO' named Regulus Therapeutics. The shares have failed to live up to their initial promise to this poi
The market cap is 91M when the last report stated 83M (including offering) in cash. Broadfin Capital recently initiated a position as well. If the data for RG-012 comes back solid, current share price will become a missed opportunity. Long RGLS
Any hope that the Wedbush Healthcare Presentation on 8/15 in NYC can add some bark to this dog?
A lot of happy campers out there. The insiders either purchased a bunch of shares at .91 cents or were they were given to them.
LA JOLLA, Calif., July 25, 2017 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company developing innovative medicines targeting microRNAs, today announced the completion of its previously announced underwritten public offering of 50,600,000 shares of its common stock, including 6,600,000 shares sold pursuant to the full exercise of an option previously granted to the underwriters. All of the shares were sold at a price to the public of $0.91 per share. Including the option exercise, the aggregate net proceeds to Regulus from the offering are expected to be approximately $43.0 million, after deducting the underwriting discounts and commissions and other estimated offering expenses payable by Regulus. Regulus intends to use the net proceeds from the offering to fund clinical development of its clinical candidates, RG-012 and RGLS4326, development of its earlier microRNA development candidates and programs, for the identification and validation of additional microRNA targets, and for capital expenditures, working capital and general corporate purposes. Leerink Partners acted as sole book-running manager in the offering. Needham & Company and Wedbush PacGrow acted as co-managers.
Back to reality. It's a waiting game again.
Confirmed what I read yesterday in the S4s. I couldn't believe what I read. It's still a gift. They are already looking at a 20% return for doing what?
President and CEO Joseph P Hagan bought 219,780 shares of RGLS stock on 07/25/2017 at the average price of $0.91. CFO Recent Trades:
CFO Daniel R. Chevallard bought 54,945 shares of RGLS stock on 07/25/2017 at the average price of $0.91.
Directors and Officers Recent Trades:
Chief R & D Officer Timothy Michael Wright bought 274,725 shares of RGLS stock on 07/25/2017 at the average price of $0.91. Director William H Rastetter bought 274,725 shares of RGLS stock on 07/25/2017 at the average price of $0.91. Director Stelios Papadopoulos bought 1,000,000 shares of RGLS stock on 07/25/2017 at the average price of $0.91.